Lilly keeps its end up in duel with Novo Nordisk - this time in diabetes

18 September 2025

US drugmaker Eli Lilly’s (NYSE: LLY) battle for dominance of the GLP-1 weight loss and diabetes market with Novo Nordisk (NOV: N) is becoming an epic.

On the same day that the Danish firm shared positive Phase III data for its experimental oral version of Wegovy (semaglutide) that showed weight-loss benefits close to those of the already approved injectable and sent its shares up 6%, Lilly has offered up some impressive data of its own.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK